• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger?

    2020-06-08 05:23:46IlariaLenciMartinaMilanaGiuseppeGrassiTommasoManziaCarloGaziaGiuseppeTisoneRobertaAngelicoLeonardoBaiocchi
    World Journal of Gastroenterology 2020年18期

    Ilaria Lenci, Martina Milana, Giuseppe Grassi, Tommaso M Manzia, Carlo Gazia, Giuseppe Tisone,Roberta Angelico, Leonardo Baiocchi

    Abstract Hepatitis B virus (HBV) recurrence after liver transplantation (LT) has been described more than 50 years ago. Similarly, to other clinical conditions, in which impairment of host immune defense favors viral replication, early reports described in details recurrence and reactivation of HBV in liver transplant recipients. The evidence of a possible, severe, clinical evolution of HBV reappearance in a significant percentage of these patients, allowed to consider,for some years, HBV positivity a contraindication for LT. Moving from the old to the new millennium this picture has changed dramatically. Several studies contributed to establish efficient prophylactic protocols for HBV recurrence and with the advent of more potent anti-viral drugs an increased control of infection was achieved in transplanted patients as well as in the general immunecompetent HBV population. Success obtained in the last decade led some authors to the conclusion that HBV is now to consider just as a “mere nuisance”.However, with regard to HBV and LT, outstanding issues are still on the table: (1)A standard HBV prophylaxis protocol after transplant has not yet been clearly defined; (2) The evidence of HBV resistant strains to the most potent antiviral agents is claiming for a new generation of drugs; and (3) The possibility of prophylaxis withdrawal in some patients has been demonstrated, but reliable methods for their selection are still lacking. The evolution of LT for HBV is examined in detail in this review together with the description of the strategies adopted to prevent HBV recurrence and their pros and cons.

    Key words: Liver transplant; Hepatitis B virus; Viral recurrence; Prophylaxis;Minimization; Antiviral drug

    INTRODUCTION

    The hepatitis B virus (HBV) is a small DNA virus belonging to theHepadnaviridaefamily[1]. Despite the adoption, in several countries, of an extended vaccination campaign starting in 1992, HBV infection still represents an important health problem with 350-400 million people infected in the world[2]. Without treatment, at least one third of patients are estimated to progress to significant liver disease, including endstage liver cirrhosis and tumors. In fact, the natural history of HBV liver disease includes a spectrum of clinical conditions ranging from a non-frequent fulminant hepatitis to HBV-related hepatocellular carcinoma and/or end-stage liver disease[3,4].While vaccination and the new antiviral drugs are effective, respectively, in avoiding HBV infection and preventing the most severe sequelae of HBV disease, liver transplantation (LT) remains the main therapeutic option in patients with more severe forms of HBV liver injury[5]. However, in the early 90's the possibility to offer LT to HBV candidates was an argument of debate. In fact, it was evident that HBV disease recurrence in the graft was severe in a significant proportion of patients[6]. Moreover,an aggressive clinical form of viral reactivation, named Fibrosing Cholestatic Hepatitis, was also described in nearly 25% of HBV transplanted patients, leading to a dramatic and rapidly progressive course[7]. Therapeutic advancement and prophylactic strategies against HBV radically changed this picture in the last three decades, allowing the consideration of HBV recurrence after LT to no longer be of concern. In this review we will describe HBV viral features, its natural history, and current outcome of HBV after LT.

    NATURAL HISTORY OF HBV

    HBV, a double stranded small DNA virus, replicating by reverse transcription, is able to convert its DNA in a covalently closed circular (ccc) form when reaching the hepatocyte's nucleus. cccDNA represents a mini-chromosome containing information for antigens (HBsAg, HBeAg, and HBcAg), X protein, and polymerase production[8].The infection route is mainly represented by vertical transmission in endemic areas.The estimated risk of acquiring the infection from an HBeAg+ mother is around 80%[9]. On the other hand, sexual or needle transmission are important paths in nonvaccinated adult patients of western countries[10]. Evolution of infection is dependent on the host, the viral genetics and virus/host interaction[3,11,12]. Vertical transmission at birth is associated (without peri-natal treatment) with a lifetime infection, usually with an immune-tolerant state[11]. This clinical situation is characterized by HBeAg positivity, high levels of HBV-DNA and normal liver function tests. Conversely, in adult normal subjects, immuno-tolerance usually lasts for 2-4 wk, the time span corresponding to the HBV incubation phase. Activation of the immune system against HBV determines: (1) Decreased HBV-DNA levels; (2) Increased liver inflammation;and (3) Elevation of serum levels of liver function tests. These features characterize the immune-active phase. This stage may evolve into: (1) Infection resolution with production of high titers of HBsAb (this target is reached by more than 90% of healthy adult individuals within 6 mo of initial HBV contact); (2) Fulminant hepatitis (rarely,≤ 0.5%); or (3) HBsAg persistence and evolution to chronic hepatitis[4]. During chronic hepatitis, the seroconversion to the HBeAg negative state (with development of HBeAb titer) represents an important achievement as it corresponds to decreased levels of HBV-DNA, liver inflammation and injury[13-15]. Moreover, HBeAg seroconversion with the consequent drop in HBV-DNA serum levels has been related to reduced fibrosis progression, histological staging, and onset of cirrhosis and hepatocellular carcinoma[16-18]. A subject with an acquired HBeAg negative state is usually defined as an inactive HBV carrier, referring to a remission state of the liver disease. Unfortunately, seroreversion to an HBeAg positive condition may occur over time (in approximately 20% of patients), also transiently, leading to a “de novo”immune-active inflammatory stage. Moreover, HBeAg loss (both spontaneous and drug induced) may determine selection in the host of pre-core mutants of HBV (not producing HBeAg). These strains are not affected, during their replicative phases, by anti-HBe antibodies, thus they determine progression of liver injury in approximately 10 to 30% of patients obtaining HBeAg loss[3,5,19]. The main clinical and virological features, in the different phases of HBV chronic infection, are reported in Table 1.From the above, it is evident that host-immune-system/virus interaction is a major determinant of the presence and severity of liver injury. This result is far more evident in subjects undergoing immune system changes related to biological or immunosuppressive therapies, including the majority of transplanted patients. In this setting severe reactivation of HBV is an element of concern[20].

    HBV DURING IMMUNE SYSTEM SUPPRESSION OR MODIFICATION (DRUG-INDUCED IMPAIRMENT OF THE IMMUNE SYSTEM AS A RISK FACTOR FOR HBV REACTIVATION)

    Reactivation of HBV is represented by sudden reappearance or increase of viral DNA in the serum of a patient with a resolved or clinically silent HBV infection[20]. This condition, which may also occur spontaneously, has been reported more frequently in patients undergoing immunosuppressive therapy for malignant or non-malignant disease[21]. In an early study in non-Hodgkin lymphoma patients under chemotherapy,HBV reactivation accounted for 72% of cases in HBsAg positive subjects[22]. More importantly, viral reappearance was also observed in HBsAb/HBcAb or only HBcAb positive subjects, thus suggesting the possibility of HBV reactivation also in conditions in which the infection was considered resolved in the past. Further studies also demonstrated HBV reappearance in non-neoplastic clinical settings such as Crohn's disease[23]or rheumatologic affections[24]. Treatment with biological agents,such as B-cell depleting (i.e., rituximab) or anti-tumor necrosis factor drugs(infliximab), carries a significant risk of HBV reactivation[25]. However, standard steroid treatment may also be responsible for HBV reappearance[26]. Evolution of viral reactivation is generally thought to occur in three separate phases[20,21]. At the beginning, a rise in HBV-DNA (at least ten-fold in comparison with baseline values) is observed during immunosuppressant treatment. In the second phase, when drugs are tapered or discontinued, the inflammatory damage begins, being triggered by the host immune defense that is also, in part, restored. In the last phase, the liver damage is repaired or may progress to end-stage liver failure. The evidence of a possible dramatic evolution of HBV reactivation in liver failure prompted the adoption of strategies to counteract this preventable occurrence. First of all, an adequate screening for HBV virus, including HBcAb, is proposed in individuals undergoing chronic therapy with immunologic modifiers. Secondly, antiviral agents able to prevent or cure this clinical condition are administered according to both viral and patient's features[27-29]. However, the clinical strategies commonly employed to prevent HBV reinfection are still lacking significant scientific evidence[27]. Therefore, the question of the best approach in different clinical scenarios remains open.

    Finally, the most important clinical setting in which HBV reappearance is a relevant issue is that of transplant. Transplanted patients usually require long-term high-dose immunosuppression to prevent rejection. In HBsAg positive patients undergoing bone marrow transplantation, HBV reactivation accounts for nearly the totality of cases[30]. Even in HBsAb/HBcAb+ subjects, reappearance of active HBV is not rare,accounting for nearly 20% of cases[31]. Starting from the early eighties, HBV reactivation was reported to be very frequent in the setting of kidney and heart transplantation, and it was characterized by the insurgence of HBV chronic hepatitis[20]. Indeed, HBV reactivation or recurrence also represents an important issue in liver transplanted patients. These subjects, in fact, share the same immunosuppressive need as other transplanted patients but, at the same time, are suffering the most important sequelae of HBV before surgery. This setting probably represents the most important clinical scenario in which dramatic HBV resurgence was observed

    Phase 1: lmmune tolerant Phase 2: lmmune active Phase 3: Asymptomatic carrier Phase 4: HBV reactivationand prophylactic measures were firstly pursued. At the same time, LT was the setting in which the risk of transplant with anti-core-HBV positive liver graft was identified.

    Table 1 Main virological and biochemical features in the different clinical phases of chronic hepatitis B in HBsAg+ patients

    HBV RECURRENCE IN THE EARLY TIMES OF LIVER TRANSPLANTATION (THE PURSUIT OF AN EFFECTIVE PROPHYLACTIC STRATEGY)

    HBV recurrence/reactivation after LT was already recognized almost 50 years ago[32].In the early 90's the feasibility of LT in HBV patients remained a crucial question since several reports observed viral recurrence in nearly all transplanted subjects, with an aggressive course in the larger part of them. While graft replacement was able to transiently reduce viral load, viral resurgence in the course of immunosuppression was related to significant liver damage and cirrhosis development[6,33]. So, at that time,LT in HBsAg positive patients was considered a high risk procedure for graft and patient loss, with an unacceptable hazard in particular in HBeAg+ subjects[34]. The disappointing results, and the need to pursue a solution for HBV patients with endstage liver disease, stimulated the research for a possible prophylactic therapy after LT. In a pioneering study conducted at Paul Brousse Hospital (Villejuif, France) in the eighties, an extended passive immune-prophylaxis was tested in HBsAg positive patients after LT[35]. Despite the monthly HBsAb immunoglobulin (HBIG)administration, 29% of patients experienced HBsAg and HBV-DNA reappearance in serum, however these data demonstrated the possibility to reduce HBV recurrence after LT. In a further European retrospective study on 372 HBV liver transplanted patients (between 1977 and 1990), a reduced rate of HBV reactivation was statistically associated with the absence of HBV-DNA before transplant and again to long-term passive immune prophylaxis with HBIG[36]. The exact mechanisms of the beneficial effects of immunoglobulin in this setting are not completely clear at present. Both reduced deletion of infected hepatocytes and prevention of viral aggression of liver cells have been suggested as possible effects[37]. Starting from the mid 90's, evidence was gathered on the role of lamivudine (Lam) treatment in repressing HBV replication[38,39]. Since, at that time, only HBIG-based prophylaxis was available after LT, and this therapy was a life-long, suboptimal, expensive treatment, the evaluation of the Lam effect in this clinical setting began. In an English study, 17 HBsAg positive patients were enrolled to receive Lam 4 wk before liver transplant and to continue 1 year thereafter[40]. Twelve out of seventeen patients were transplanted. In them, Lam induced a loss of HBsAg and undetectable HBV-DNA serum levels within 4 wk of treatment and after transplant. Moreover, liver histology did not show features suggesting HBV recurrence after LT, and these results were obtained without concomitant HBIG immune prophylaxis. Unfortunately, in the same study, selection of a resistant strain to Lam was observed in one patient after 20 wk of treatment. This occurrence was characterized by reactivation of HBV and evidence of chronic hepatitis on liver tissue after 1 year. Similar to that observed in HIV therapy[41], HBV strains not-responding to Lam were characterized by mutation of polymerase at the highly conserved YMDD motif[42-44]. With regard to liver transplanted HBV patients,extended follow up of Lam resistant patients was lately reported. Resistance to Lam began to occur, typically, six months after its introduction and was sometimes characterized by severe disease recurrence[45,46]. A combination of Lam therapy with HBIG was then attempted in order to further reduce HBV recurrence after LT. In a study, fourteen HBsAg positive LT patients were treated with Lam plus HBIG[47]. In a median follow-up of one year, all patients were HBV-DNA negative in serum, thus demonstrating the superiority of combination therapy in comparison with monotherapy with either Lam or HBIG. These data were also confirmed in a study with an extended (average 31 mo) follow-up[48]. Thus, the past millennium ended with the positive perspective that prevention of HBV recurrence/reactivation in HBsAg transplanted subjects was feasible. On the basis of these results, the possible exclusion of HBV subjects from transplant lists was largely reexamined.

    HBV RECURRENCE/REACTIVATION AFTER LIVER TRANSPLANTATION IN THE THIRD MILLENNIUM (TESTING NEW THERAPEUTIC APPROACHES AND DRUGS)

    The efficacy of passive immunization, in association with Lam, was again demonstrated in retrospective studies after the year 2000[49,50]. However, since this strategy was flawed by the relevant cost of HBIG and the need of life-long administration, the possibility to induce active immunization in HBV liver transplanted patients was examined.

    HBV vaccination

    In a study on 17 HBsAg+, HBeAg and HBV-DNA negative liver transplanted patients(after at least 18 mo of HBIG treatment), the double dose administration of HBV vaccine at baseline, 1 and 6 mo was tested[51]. After vaccination 84% of patients developed an HBsAb titer. During a further follow-up of 14 mo, HBsAg reappearance was not observed. These positive results were not replicated in a following study in which three reinforced and sequential cycles of HBV vaccination determined only a 17.6% HBsAb seroconversion in HBV transplanted patients[52]. In an editorial in the same journal, the limits of this strategy in transplanted patients were discussed,underscoring the scarce vaccine efficacy during immunosuppression and the long time needed to reconstitute the immune system after its depression[53]. In conclusion, it was confirmed that HBIG and antiviral therapy were regarded as the most appropriate measures against HBV recurrence after LT[54].

    Adefovir dipivoxil

    With regard to antiviral agents, in those years, a new drug implemented the armamentarium for the therapy of HBV. Adefovir dipivoxil (ADV), a nucleotide analog inhibiting viral reverse transcriptase that was abandoned for treatment of HIV because of kidney damage when used at high dose, was licensed for HBV treatment since it was active at lower, non-toxic levels for this virus (10 mg/d). ADV treatment in the majority of immune-competent HBsAg patients (both HBeAg positive or negative) determined a clear reduction of HBV-DNA, improvement of liver histology,and normalization of liver enzymes after a 48 wk course[55,56]. Moreover, emergence of ADV resistant mutants was not observed during these trials. Despite the fact that possible long-term viral resistance to ADV remained to be assessed, the efficacy of this new antiviral drug allowed hope for a new era in which HBV could be regarded as just a “mere nuisance”[57]. Soon, ADV was employed for the treatment of Lam resistant HBV after transplant[58]. Again, a significant improvement of liver function was recorded in nearly 90% of patients, and no resistant HBV strains were selected after 48 wk of therapy. However, ADV viral resistance was then observed with prolonged follow-up[59,60]. This was characterized by a novelN236Tmutation of HBV polymerase.In spite of this, the clinical evolution in patients was not worrisome since these ADV resistant strains were easily suppressed by Lam concomitant therapy. On the base of these findings, a possible Lam + ADV concomitant treatment for HBV was suggested[61]. Data from a systematic review including 2162 HBV LT patients[62]identified the following as possible risk factors for HBV recurrence: (1) Being HBVDNA positive at transplant (8.5%vs4%); (2) Administration of low dose HBIG in the first week after LT (6.1%vs3.5%); and (3) Combination therapy with HBIG + LamvsHBIG + ADV (6.1%vs2%). This picture was destined to undergo further changes with the advent of new nucleos(t)ide analogues with high genetic barriers.

    New high genetic barrier nucleos(t)ide analogues.

    Starting from 2012, entecavir (ETV) and tenofovir dipivoxyl (TDF) were proposed by several guidelines as a first line of treatment for chronic HBV hepatitis[5,63]. In fact, both drugs were demonstrated to be very effective in clinical studies, to have an excellent safety profile, and to be affected by a minimal or absent emergence of resistant HBV strains[64-68]. In a systematic review[69]on nucleos(t)ide analogues for HBV prophylaxis after LT, the comparison between Lam + HBIGvsthe association of ETV or TDF with HBIG demonstrated the superiority of the latter treatments (HBV recurrence rate 6.1%vs1%,P< 0.001). Moreover, in the same analysis, preliminary data evidenced slightly better results with either ETV or TDF monotherapy (after HBIG discontinuation) in comparison with the canonical Lam + HBIG prophylaxis (HBV recurrence rate 3.9%vs6.1%, difference not statistically significant). These findings introduced the concept of a possible minimization of HBV prophylaxis after LT, stimulating research with this target.

    TOWARD HBV PROPHYLAXIS MINIMIZATION AFTER LT

    Several strategies have been designed to minimize HBV prophylaxis after LT. The most relevant are described in the following subparagraphs with the corresponding results. Main studies on this issue are also summarized in Table 2.

    HBIG dose reduction

    Since long-term administration of HBIG was a critical point for its high cost, that would easily reach $100.000/pts/year[70], several attempts were carried out to reduce HBIG administration and acceptable results obtained. In a 2004 study conducted in our Unit (Liver Transplant Center, University of Rome Tor Vergata), we evaluated the possibility to prevent HBV recurrence after LT by administering HBIG on demand(when HBsAb serum levels were ≤ 70 IU/L) instead of the standard monthly administration[71]. Moreover, in the same study, two different HBIG doses (5000 IU or 2000 IU) were employed. In eleven HBV patients, at low risk for reactivation (HBsAg,HBV-DNA negative) and under concomitant Lam therapy, this strategy did not determine any HBV reactivation for 1 year follow up. On the other hand, the treatment based on administration of 2000 IU HBIG on demand reduced the cost of passive immune-prophylaxis by more than 50%. In 2007, the Australasian Liver Transplant Study Group assessed the association of very-low HBIG doses (400-800 IU)+ Lam on HBV recurrence after LT[72]. This strategy accounted for a modest HBV recurrence risk of 4% in 5 years, and the results were considered highly satisfactory since the majority of patients (85%) were HBV-DNA positive at transplant.

    High-genetic barrier nucleos(t)ide analogues monotherapy

    The advent of high-genetic barrier nucleos(t)ide analogues ETV and TDF, allowed speculation on a possible prophylaxis without HBIG. ETV monotherapy, tested on 80 patients undergoing LT for HBV, was able to suppress HBV-DNA (under the lower detection limit) in nearly 99% of cases after 24 mo[73]. Extended follow up of this study(8 years) demonstrated a 92% loss of HBsAg, while HBV-DNA was undetectable in all[74]. On the other hand, discontinuation of HBIG in transplanted patients treated with TDF + HBIG did not change any viral or patient profile in a 72 wk follow-up[75].Good results with either ETV and TDF were also replicated in other studies[76,77]. In a 5-year follow up in patients discontinuing HBIG and commencing either ETV or TDF after LT, HBsAg+ seroconversion occurred in 8% of cases, while HBV-DNA reappearance was not observed[78]. On the basis of these results, the most authoritative guidelines in the field now contemplate ETV or TDF monotherapy as an efficient prophylactic measure in subjects at low risk of HBV recurrence after LT[78,79].

    Complete withdrawal of HBV prophylaxis

    In the past years, our group examined a more radical approach to HBV prophylaxis minimization. This was characterized by the complete withdrawal of antiviral drugs in well selected HBV transplanted patients. We started with the assumption that reappearance of HBV after transplantation was dependent on the presence of cccDNA in the graft. Contrary to a North American study, (including several HBeAg/HBVDNA+ patients at LT) in which total HBV-DNA and cccDNA were detected in liver tissue in 83% and 18% of cases, respectively[80], in a preliminary evaluation of HBsAg patients transplanted in our center, only 1 out of 44 was found to be positive for cccDNA[81]. Among those that were negative for liver ccc-DNA, 30 were selected and underwent sequential withdrawal of HBIG and Lam. The majority of patients (83%,n= 25) did not experience any HBV recurrence in a median follow up longer than 2 years. Five patients came back to an HBsAg positive status. Prompt resumption of HBV prophylaxis allowed infection control, avoiding any significant clinical impairment[82]. From this study, we concluded that complete withdrawal of HBV prophylaxis after LT was feasible in patients with negative serum HBV-DNA and tissue cccDNA at transplant. An editorial, in the same journal, wisely observed that the time had come for an individualized prophylaxis in HBV transplanted patients[83].In fact, recurrence of HBV was mainly reported in patients who were HBV-DNA positive at transplant (> 100.000 copies/mL) and/or HBeAg+[36,72,84]. On the other hand, those not falling in the above category were considered at low risk for HBV recurrence. In this perspective, the target of HBV-DNA negativity was to be pursued before transplant in order to perhaps minimize prophylaxis after grafting. Conversely,for high-risk patients (HBeAg, HBV-DNA positive), more robust antiviral protocols were to be considered.

    Table 2 Main studies examining prophylaxis minimization in hepatitis B virus liver transplanted patients, employing different approaches

    More recently, data on longer (6-year) follow up of this original cohort were published by our group[85]. Only 3 patients needed prophylaxis resumption (10%). Of the whole cohort, 93% remained HBsAg negative and 100% had undetectable HBVDNA. More interestingly, 60% of patients spontaneously developed an HBsAb titer >10 IU/L. This was probably related to the minimization or withdrawal of antirejection therapy that is routinely pursued in our center in patients transplanted for several years. Comment on this study appeared in a new editorial[86]. While these data were encouraging, it underscored that limits remained in the identification of low risk patients. cccDNA techniques, in fact, needed to be standardized to be widely and consistently applicable in clinical settings, but on the other hand, extra-hepatic HBV reservoirs were still a possible issue of concern.

    CONCLUSION

    Several important achievements were obtained in the last fifty years with regard to HBV liver transplanted patients. The original exclusion of these subjects from LT waiting lists, due to poor outcome, was counteracted by the adoption of effective measures to prevent HBV recurrence. At present, high genetic barrier anti-viral drugs are giving an important contribution in transplanted patients, as well as in the HBV immune-competent population. Recently, tenofovir alafenamide, a TDF analog with improved renal safety and increased ability to reduce alanine aminotransferase, was employed in LT patients with good results[87]. However, of concern, HBV mutants with resistance to TDF (the drug with the highest genetic barrier) were recently identified, underscoring the need of a new generation of HBV agents to be employed,at least, as a rescue therapy[88]. The future of LT for HBV is not completely predictable at this stage. It will, however, depend on the global burden of HBV and the possible discovery of HBV eradicating drugs.

    精品一区二区三区人妻视频| 久久国产乱子免费精品| 国产激情偷乱视频一区二区| 久久久精品大字幕| 国产在线男女| 看黄色毛片网站| 亚洲国产精品合色在线| 身体一侧抽搐| www日本黄色视频网| avwww免费| 国产伦人伦偷精品视频| 97超级碰碰碰精品色视频在线观看| 日日夜夜操网爽| 日本-黄色视频高清免费观看| 美女免费视频网站| 少妇猛男粗大的猛烈进出视频 | 国产精品久久视频播放| 高清在线国产一区| av天堂中文字幕网| 搡老岳熟女国产| 美女高潮喷水抽搐中文字幕| 九色成人免费人妻av| 国产国拍精品亚洲av在线观看| 有码 亚洲区| 俄罗斯特黄特色一大片| 日韩av在线大香蕉| 男插女下体视频免费在线播放| 国产亚洲av嫩草精品影院| 亚洲成人久久爱视频| 一级av片app| av黄色大香蕉| 国产在线男女| 欧美日韩瑟瑟在线播放| 1000部很黄的大片| 亚洲国产精品sss在线观看| 国产精品一及| 亚洲18禁久久av| 国产精品免费一区二区三区在线| 亚洲av免费在线观看| 久久久久久久久久黄片| 亚洲精华国产精华精| 中文字幕免费在线视频6| 亚洲国产精品合色在线| 亚洲av.av天堂| 国产精品久久视频播放| 欧美一级a爱片免费观看看| 欧美区成人在线视频| 男女做爰动态图高潮gif福利片| 国产高清有码在线观看视频| 99久久成人亚洲精品观看| 欧美不卡视频在线免费观看| 色综合亚洲欧美另类图片| 丝袜美腿在线中文| 国产又黄又爽又无遮挡在线| 又紧又爽又黄一区二区| 国产高清视频在线观看网站| 国产精品一区www在线观看 | 午夜亚洲福利在线播放| 日本三级黄在线观看| 日韩精品中文字幕看吧| 高清日韩中文字幕在线| 亚洲天堂国产精品一区在线| 免费观看在线日韩| 国产黄a三级三级三级人| 精品一区二区三区视频在线| 成人综合一区亚洲| 婷婷精品国产亚洲av在线| 淫秽高清视频在线观看| 亚洲欧美精品综合久久99| 国产成人一区二区在线| 99久久久亚洲精品蜜臀av| 精品一区二区免费观看| 午夜精品在线福利| 少妇的逼水好多| 神马国产精品三级电影在线观看| 国产一区二区激情短视频| 国产真实乱freesex| 久久久久久久亚洲中文字幕| 又粗又爽又猛毛片免费看| 91久久精品国产一区二区三区| 亚洲四区av| 亚洲在线自拍视频| 欧美+亚洲+日韩+国产| 综合色av麻豆| 女的被弄到高潮叫床怎么办 | 亚洲精品久久国产高清桃花| 蜜桃亚洲精品一区二区三区| 午夜视频国产福利| 美女大奶头视频| 一区二区三区四区激情视频 | 国产69精品久久久久777片| 欧美日韩国产亚洲二区| 久久99热这里只有精品18| 在线观看午夜福利视频| 成人一区二区视频在线观看| 婷婷精品国产亚洲av在线| av在线天堂中文字幕| 啦啦啦啦在线视频资源| 国产乱人伦免费视频| 精品一区二区免费观看| 亚洲成人久久爱视频| 亚洲精华国产精华液的使用体验 | 日韩欧美 国产精品| 国产精品三级大全| 极品教师在线视频| 国产精品亚洲一级av第二区| 精品久久国产蜜桃| 成人亚洲精品av一区二区| 国产黄片美女视频| 国产黄a三级三级三级人| 一级黄片播放器| 欧美日韩国产亚洲二区| 国产91精品成人一区二区三区| 春色校园在线视频观看| 国产精品人妻久久久久久| 亚洲美女黄片视频| 免费搜索国产男女视频| av黄色大香蕉| 此物有八面人人有两片| 亚洲精华国产精华精| 国产高清三级在线| 97碰自拍视频| 男女视频在线观看网站免费| 成人综合一区亚洲| eeuss影院久久| 97热精品久久久久久| 天堂网av新在线| 22中文网久久字幕| 女人十人毛片免费观看3o分钟| 久久精品国产鲁丝片午夜精品 | 日本黄色片子视频| 黄色日韩在线| 哪里可以看免费的av片| 久久草成人影院| av天堂中文字幕网| 亚洲最大成人av| 91麻豆av在线| 国产一区二区三区视频了| 久久热精品热| 欧美高清性xxxxhd video| 欧美最新免费一区二区三区| 久久久久久大精品| 直男gayav资源| 免费观看在线日韩| 国产伦人伦偷精品视频| 亚洲第一电影网av| 日本免费一区二区三区高清不卡| 两个人视频免费观看高清| 一本精品99久久精品77| 自拍偷自拍亚洲精品老妇| 一个人观看的视频www高清免费观看| 一本精品99久久精品77| 中文字幕av成人在线电影| 日韩欧美免费精品| 久久国产精品人妻蜜桃| 国产真实伦视频高清在线观看 | 亚洲国产精品合色在线| 国产一区二区亚洲精品在线观看| 色av中文字幕| 老熟妇仑乱视频hdxx| 18禁在线播放成人免费| 国产精品永久免费网站| 国产av在哪里看| 性插视频无遮挡在线免费观看| 国产成人a区在线观看| 波多野结衣高清无吗| 99国产精品一区二区蜜桃av| 可以在线观看毛片的网站| 国产午夜精品久久久久久一区二区三区 | 看十八女毛片水多多多| 久久久久久久午夜电影| 久久久久精品国产欧美久久久| 日本免费一区二区三区高清不卡| 97热精品久久久久久| 成人综合一区亚洲| 日本黄色视频三级网站网址| av在线观看视频网站免费| 精品久久久久久久久av| 成年人黄色毛片网站| 国产色爽女视频免费观看| 全区人妻精品视频| 99久久中文字幕三级久久日本| 国产精品嫩草影院av在线观看 | 麻豆国产97在线/欧美| 国产精品伦人一区二区| 久久热精品热| 午夜免费激情av| 亚洲午夜理论影院| 色吧在线观看| 可以在线观看的亚洲视频| 欧美3d第一页| 韩国av一区二区三区四区| 波多野结衣高清无吗| 国产一区二区在线av高清观看| 午夜福利视频1000在线观看| 亚洲国产精品久久男人天堂| 国产免费男女视频| 国产av在哪里看| 国内毛片毛片毛片毛片毛片| 国产精品伦人一区二区| 久久久久久久久久成人| 少妇人妻一区二区三区视频| 亚洲av第一区精品v没综合| 国产69精品久久久久777片| 黄色一级大片看看| 18禁黄网站禁片免费观看直播| 99九九线精品视频在线观看视频| 热99re8久久精品国产| 看黄色毛片网站| 欧美又色又爽又黄视频| av在线天堂中文字幕| 久久精品国产99精品国产亚洲性色| 亚洲,欧美,日韩| 免费看a级黄色片| 深爱激情五月婷婷| 久久99热6这里只有精品| 久久精品国产亚洲av涩爱 | 日韩欧美精品免费久久| 中文字幕人妻熟人妻熟丝袜美| 国产乱人伦免费视频| 最好的美女福利视频网| 国产黄a三级三级三级人| 99热这里只有是精品在线观看| 免费av观看视频| 久久久午夜欧美精品| or卡值多少钱| 美女高潮的动态| 老司机深夜福利视频在线观看| 少妇人妻一区二区三区视频| 日本a在线网址| 成熟少妇高潮喷水视频| 一个人看的www免费观看视频| 99久久精品热视频| 亚洲欧美清纯卡通| 黄色欧美视频在线观看| 国产高清视频在线播放一区| 久久精品综合一区二区三区| 中文在线观看免费www的网站| 国产av在哪里看| 国产亚洲av嫩草精品影院| 国产精品乱码一区二三区的特点| 欧美精品国产亚洲| 天堂影院成人在线观看| 亚洲成人精品中文字幕电影| av女优亚洲男人天堂| 看十八女毛片水多多多| 我要看日韩黄色一级片| 国产成人a区在线观看| 久久精品国产自在天天线| 狂野欧美白嫩少妇大欣赏| 国产视频一区二区在线看| 国产精品女同一区二区软件 | 我要看日韩黄色一级片| 男女那种视频在线观看| 97人妻精品一区二区三区麻豆| 午夜精品久久久久久毛片777| 99久久九九国产精品国产免费| 九九热线精品视视频播放| 最近最新中文字幕大全电影3| 亚洲自拍偷在线| 别揉我奶头~嗯~啊~动态视频| 伦理电影大哥的女人| 亚洲av日韩精品久久久久久密| av黄色大香蕉| 久久这里只有精品中国| 91麻豆av在线| 国产三级在线视频| 亚洲欧美激情综合另类| 精品人妻偷拍中文字幕| 国内精品宾馆在线| 亚洲专区国产一区二区| 免费人成视频x8x8入口观看| 欧美绝顶高潮抽搐喷水| 国产精品女同一区二区软件 | 亚洲欧美日韩卡通动漫| 色5月婷婷丁香| 久久人人爽人人爽人人片va| 国产综合懂色| 久久久久久伊人网av| 男人狂女人下面高潮的视频| 男女啪啪激烈高潮av片| 国产人妻一区二区三区在| 又紧又爽又黄一区二区| 欧美激情在线99| 免费av观看视频| АⅤ资源中文在线天堂| 精品久久久久久久久久免费视频| 我的女老师完整版在线观看| 亚洲不卡免费看| 免费不卡的大黄色大毛片视频在线观看 | 如何舔出高潮| 国产精品无大码| 国产精品美女特级片免费视频播放器| 国产女主播在线喷水免费视频网站 | 毛片女人毛片| 久久香蕉精品热| 亚洲欧美日韩卡通动漫| 黄色配什么色好看| 日本a在线网址| 中文资源天堂在线| 国产精品自产拍在线观看55亚洲| 小蜜桃在线观看免费完整版高清| 亚洲av日韩精品久久久久久密| 国产成人a区在线观看| 丰满的人妻完整版| 欧美国产日韩亚洲一区| 精品久久久久久久久亚洲 | eeuss影院久久| 麻豆av噜噜一区二区三区| 日韩一本色道免费dvd| 久久九九热精品免费| 国产白丝娇喘喷水9色精品| 天美传媒精品一区二区| 一个人看视频在线观看www免费| 日韩强制内射视频| 午夜日韩欧美国产| 狂野欧美激情性xxxx在线观看| 啦啦啦观看免费观看视频高清| 免费电影在线观看免费观看| 最近最新中文字幕大全电影3| 久久婷婷人人爽人人干人人爱| 成年女人毛片免费观看观看9| 国产精品久久久久久亚洲av鲁大| 亚洲欧美激情综合另类| 自拍偷自拍亚洲精品老妇| 51国产日韩欧美| 1000部很黄的大片| 国产真实乱freesex| 国产一级毛片七仙女欲春2| videossex国产| 国内精品一区二区在线观看| 91久久精品国产一区二区成人| 国产精品乱码一区二三区的特点| 久久6这里有精品| 亚洲,欧美,日韩| 听说在线观看完整版免费高清| 可以在线观看毛片的网站| 亚洲熟妇中文字幕五十中出| 99热精品在线国产| 国产精品日韩av在线免费观看| 中文字幕久久专区| 久久人人爽人人爽人人片va| 可以在线观看毛片的网站| 长腿黑丝高跟| 成人一区二区视频在线观看| 欧美日韩中文字幕国产精品一区二区三区| 午夜免费男女啪啪视频观看 | 午夜激情福利司机影院| 亚洲真实伦在线观看| 国产中年淑女户外野战色| 国产精品综合久久久久久久免费| 人妻少妇偷人精品九色| 欧美+亚洲+日韩+国产| 国产人妻一区二区三区在| 国产女主播在线喷水免费视频网站 | 久久久久性生活片| 亚洲真实伦在线观看| 免费在线观看成人毛片| 最好的美女福利视频网| 99久国产av精品| 亚洲精品日韩av片在线观看| 国产亚洲欧美98| 欧美三级亚洲精品| 九色成人免费人妻av| bbb黄色大片| 老司机深夜福利视频在线观看| 婷婷六月久久综合丁香| 真人一进一出gif抽搐免费| 两性午夜刺激爽爽歪歪视频在线观看| 国产精品国产三级国产av玫瑰| 干丝袜人妻中文字幕| 久久精品91蜜桃| 国内毛片毛片毛片毛片毛片| 99热这里只有是精品50| 18禁黄网站禁片免费观看直播| 精品人妻熟女av久视频| 国产精品98久久久久久宅男小说| 国国产精品蜜臀av免费| 久久久久精品国产欧美久久久| 日本五十路高清| a在线观看视频网站| 国产精品99久久久久久久久| 亚洲av成人av| 九九爱精品视频在线观看| 日日啪夜夜撸| 久久国内精品自在自线图片| 日韩精品中文字幕看吧| 嫩草影院精品99| 国产在线精品亚洲第一网站| 深夜精品福利| 看片在线看免费视频| 亚洲精品国产成人久久av| 亚洲精华国产精华液的使用体验 | 亚洲熟妇熟女久久| 麻豆一二三区av精品| 九九热线精品视视频播放| 国产亚洲精品av在线| 免费观看人在逋| 看免费成人av毛片| 欧美xxxx黑人xx丫x性爽| 一级黄色大片毛片| 国内精品宾馆在线| 又粗又爽又猛毛片免费看| aaaaa片日本免费| 免费看a级黄色片| 亚洲精品456在线播放app | 黄色欧美视频在线观看| a级毛片a级免费在线| 色5月婷婷丁香| 日本a在线网址| 亚洲色图av天堂| 中国美女看黄片| 九九在线视频观看精品| 亚洲欧美日韩高清专用| 婷婷精品国产亚洲av在线| 性欧美人与动物交配| 五月伊人婷婷丁香| 色尼玛亚洲综合影院| 我的女老师完整版在线观看| 美女被艹到高潮喷水动态| 亚洲最大成人av| 内射极品少妇av片p| 国产黄色小视频在线观看| 人妻制服诱惑在线中文字幕| 最后的刺客免费高清国语| 日本黄大片高清| 一进一出抽搐动态| 少妇人妻一区二区三区视频| 在线播放国产精品三级| 亚洲熟妇熟女久久| 国产精品亚洲美女久久久| 日韩av在线大香蕉| 午夜福利在线观看免费完整高清在 | 亚洲内射少妇av| 人人妻人人看人人澡| 免费大片18禁| 波野结衣二区三区在线| 真人一进一出gif抽搐免费| 亚洲 国产 在线| 国产亚洲欧美98| 午夜a级毛片| 国产色爽女视频免费观看| 国产黄a三级三级三级人| 亚洲国产日韩欧美精品在线观看| 亚洲欧美日韩卡通动漫| 久久精品91蜜桃| 国产成人av教育| 无遮挡黄片免费观看| 国产精品久久电影中文字幕| 亚洲熟妇中文字幕五十中出| 日日摸夜夜添夜夜添av毛片 | 国内精品美女久久久久久| 国产精品一及| 国产大屁股一区二区在线视频| 久久人人爽人人爽人人片va| 欧美日韩国产亚洲二区| 欧美xxxx黑人xx丫x性爽| 亚洲一区二区三区色噜噜| 少妇人妻精品综合一区二区 | 少妇高潮的动态图| 国内精品宾馆在线| 最好的美女福利视频网| 国内久久婷婷六月综合欲色啪| 国产高清视频在线观看网站| av在线亚洲专区| 啪啪无遮挡十八禁网站| 国产免费一级a男人的天堂| 免费在线观看成人毛片| 热99在线观看视频| 亚洲三级黄色毛片| 欧美日韩乱码在线| 亚洲中文字幕日韩| 在线看三级毛片| 久久精品夜夜夜夜夜久久蜜豆| 国产在线精品亚洲第一网站| 极品教师在线免费播放| 变态另类成人亚洲欧美熟女| 成人av在线播放网站| 国产一区二区三区av在线 | 老司机午夜福利在线观看视频| 久久精品国产亚洲av香蕉五月| av黄色大香蕉| 久久久久久国产a免费观看| 亚洲va日本ⅴa欧美va伊人久久| 久久午夜福利片| 国产爱豆传媒在线观看| 久久草成人影院| 美女黄网站色视频| 中国美白少妇内射xxxbb| 最近最新免费中文字幕在线| 国产爱豆传媒在线观看| 成人亚洲精品av一区二区| 88av欧美| 亚洲性久久影院| 欧美xxxx黑人xx丫x性爽| 久久久久久九九精品二区国产| 91精品国产九色| 亚州av有码| 日日摸夜夜添夜夜添av毛片 | 大型黄色视频在线免费观看| 亚洲avbb在线观看| 久久人人爽人人爽人人片va| 免费看光身美女| 亚洲最大成人手机在线| 人人妻人人澡欧美一区二区| 级片在线观看| 国产精品自产拍在线观看55亚洲| 又紧又爽又黄一区二区| 很黄的视频免费| 久久99热这里只有精品18| 免费一级毛片在线播放高清视频| 亚洲性夜色夜夜综合| 91在线观看av| 国内毛片毛片毛片毛片毛片| 国产熟女欧美一区二区| 国产亚洲欧美98| 草草在线视频免费看| 成人一区二区视频在线观看| 99国产精品一区二区蜜桃av| 国产熟女欧美一区二区| 男人和女人高潮做爰伦理| 免费观看在线日韩| 又爽又黄无遮挡网站| 色综合亚洲欧美另类图片| 国产aⅴ精品一区二区三区波| 亚洲av美国av| 亚洲国产日韩欧美精品在线观看| 国产成人影院久久av| av中文乱码字幕在线| 亚洲第一电影网av| 嫩草影院精品99| 日本成人三级电影网站| 日本撒尿小便嘘嘘汇集6| 丰满的人妻完整版| 中文资源天堂在线| 午夜免费激情av| 久久人人精品亚洲av| 老女人水多毛片| 色综合站精品国产| 一级黄色大片毛片| 亚洲成a人片在线一区二区| 久久久久久久久大av| 在线播放无遮挡| 俺也久久电影网| 久久人人精品亚洲av| 日本一本二区三区精品| 搡老妇女老女人老熟妇| 国产精品一区二区性色av| 亚洲av不卡在线观看| 久久人人爽人人爽人人片va| 色综合色国产| 亚洲成人久久爱视频| 草草在线视频免费看| 午夜日韩欧美国产| 久久久久九九精品影院| 亚洲美女黄片视频| 国产色婷婷99| 欧美性猛交╳xxx乱大交人| 老司机深夜福利视频在线观看| av视频在线观看入口| 一个人看视频在线观看www免费| 岛国在线免费视频观看| 亚洲最大成人中文| 一个人观看的视频www高清免费观看| 免费无遮挡裸体视频| 在线观看午夜福利视频| 动漫黄色视频在线观看| 好男人在线观看高清免费视频| 亚洲 国产 在线| 麻豆av噜噜一区二区三区| 午夜福利欧美成人| 国产综合懂色| 国产一区二区激情短视频| 亚洲午夜理论影院| 亚洲七黄色美女视频| 又紧又爽又黄一区二区| 日韩亚洲欧美综合| 亚洲av中文av极速乱 | 亚洲欧美日韩无卡精品| 欧美成人免费av一区二区三区| 久久99热这里只有精品18| 成人美女网站在线观看视频| 久久久久久久午夜电影| 欧美+日韩+精品| 亚洲精华国产精华精| 身体一侧抽搐| 色视频www国产| 最新中文字幕久久久久| 最近最新中文字幕大全电影3| 欧美日韩中文字幕国产精品一区二区三区| 一级黄色大片毛片| 又爽又黄无遮挡网站| 亚洲精品粉嫩美女一区| av天堂中文字幕网| 女人被狂操c到高潮| 少妇的逼好多水| 三级男女做爰猛烈吃奶摸视频| 99热这里只有是精品在线观看| 国产男人的电影天堂91| 国产精品98久久久久久宅男小说| 色视频www国产| 床上黄色一级片| 国产高清不卡午夜福利| 欧美中文日本在线观看视频| 色哟哟·www| 国产亚洲精品久久久久久毛片| 99久国产av精品| 露出奶头的视频| 色哟哟哟哟哟哟| 久久精品国产亚洲av天美| 我要搜黄色片| 在线观看av片永久免费下载| 久久人妻av系列| 一个人观看的视频www高清免费观看| 国产男靠女视频免费网站|